Iron for Health & Longevity - Quick Reference Sheet

Iron for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 Audit

Iron is not a longevity supplement. The body can take it in and can barely eliminate it. When stores are empty, bringing levels back restores blood oxygen-carrying protein, eases fatigue, and can quiet restless legs; intravenous iron in iron-deficient heart failure is tied to fewer hospitalizations. Extra iron with already-full stores has not shown a longevity gain. (Full Review)

Protocol

Standard repletion (hematology/primary care)
40–100 mg elemental iron
Single daily or alternate-day dose for 8–12 weeks, then until ferritin recovers
Time of day
Morning
Away from coffee, tea, calcium, and high-phytate meals; vitamin C–containing food can sit with the dose
Baseline biomarkers
Ferritin, TSAT, hemoglobin, CRP
These markers decide whether to treat, the route, and when to stop
Time to effect
Hemoglobin
Moves by 2 weeks
Normalizes over 4–8 weeks if losses are controlled
Restless legs
2–12 weeks
Can shift with repletion when iron is low
Fatigue
2–12 weeks
Unexplained fatigue when ferritin is low but hemoglobin is normal

Benefits

Contraindications
  • Confirmed hereditary hemochromatosis or other primary iron-overload disease (HFE C282Y homozygosity with TSAT ≥45% and ferritin above sex-specific thresholds)
  • Secondary iron overload (repeated transfusions, thalassemia with high ferritin, sideroblastic anemia)
  • Unexplained TSAT ≥45% with elevated ferritin pending cause-finding
  • Iron-replete men and postmenopausal women without a documented deficiency or a disease-specific intravenous-iron indication
  • Active serious infection until the infection is controlled (especially for intravenous iron)
  • Known serious hypersensitivity to a given intravenous iron product (that product only)
Key Interactions
  • Levothyroxine (separate by at least 4 hours)
  • Tetracycline and fluoroquinolone antibiotics (ciprofloxacin, doxycycline; iron 2 hours before or 3 hours after)
  • Acid reducers (omeprazole, pantoprazole, famotidine)
  • Calcium, zinc, magnesium, and antacids (separate by ≥2 hours)
  • Vitamin C (potentiating)
  • Other iron products and iron-fortified medical foods (past 45 mg/day adult upper intake level)
  • ACE inhibitors (lisinopril, enalapril) (monitor)

Risk & Side Effects

  • High: Gastrointestinal intolerance of oral iron; Hypophosphatemia after ferric carboxymaltose; Infection after intravenous iron; Infusion reactions and rare anaphylaxis with intravenous iron
  • Medium: Iron overload and organ injury when regulation fails or intake is unsupervised; Acute iron poisoning, especially in children; Higher death rates with supplemental iron in older women; Cardiometabolic associations of high heme-iron intake
  • Low:
  • Speculative: Faster cellular aging from catalytic iron in already-replete users; Shift in gut microbial balance

Monitoring

Marker Target Why
Ferritin 50–150 ng/mL (restless legs often ≥75–100) Stored iron
TSAT 20–45% Iron immediately available to tissues
Hemoglobin Men ~13.5–15.5 g/dL; women ~12.5–14.5 g/dL Oxygen-carrying capacity
Serum iron + TIBC No established functional target Separates deficiency from inflammation
CRP <1.0 mg/L Confounds ferritin
Phosphate (after FCM) 2.5–4.5 mg/dL Detects FCM phosphate wasting

Cadence: Baseline before treatment-dose iron; 6–8 weeks after oral repletion starts; 3–6 months after stores refill; every 6–12 months if bleeding, endurance training, gut disease, or prior overload remains. Delayed ferritin after intravenous iron; phosphate 2–6 weeks after ferric carboxymaltose

Qualitative Assessment

  • Daytime energy and exercise tolerance
  • Restless-legs urge and sleep continuity
  • Gut comfort, stool color, and nausea after doses
  • Cognitive clarity and cold intolerance
  • In overload phenotypes: joint pain, bronze skin, new diabetes, unexplained liver-enzyme rise